{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-036440","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.522422+00:00","generated_at":"2026-06-12T18:53:22.391756+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioAtla reports Q2 2023 net loss of $35.8M; cash $168.7M funds into 2025","bullets":["Net loss of $35.8M for Q2 2023 vs $28.9M in Q2 2022; R&D expenses rose to $31.0M from $20.7M.","Cash at June 30, 2023 was $168.7M, down from $215.5M at Dec 31, 2022; expected to fund operations into 2025.","Phase 2 potentially registrational BA3011 UPS study continues enrolling; FDA meeting request submitted for NSCLC study.","CAB-CTLA-4 BA3071 cleared fifth cohort (5 mg/kg) with no DLTs; sixth cohort enrolling; Phase 1 data readout on track for 2H23.","Anticipated data across BA3021 NSCLC, melanoma, SCCHN to enable 'go' decision for indications in 2H23."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-036440","json":"https://secwatch.observer/filing/0000950170-23-036440.json","markdown":"https://secwatch.observer/filing/0000950170-23-036440.md","text":"https://secwatch.observer/filing/0000950170-23-036440.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023036440/0000950170-23-036440-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023036440/bcab-20230801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T18:53:22.391756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e58a0640ea33819e973f811818d82f44f3dfb7d","claim":"BioAtla, Inc. reported the quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the sa.","evidence_excerpt":"Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the same quarter in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023036440/0000950170-23-036440-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the sa"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}